{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:16:48Z","timestamp":1780391808444,"version":"3.54.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>When initiating urate-lowering therapy, using anti-inflammatory prophylaxis therapy for at least 3 to 6\u200amonths is strongly recommended. Previous studies have found that zhengqing fengtongning sustained-release tablets (sinomenine) can improve inflammation in the acute phase of gout; however, the efficacy of urate-lowering therapy in reducing frequency of acute flares still needs to be investigated. The aim of the present study is to explore the efficacy and safety of sinomenine for prophylaxis of acute flares when initiating urate-lowering therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and analysis:<\/jats:title>\n            <jats:p>This randomized, placebo-controlled, double-blinded trial will include a total of 210 gout patients who meet the study criteria. The patients will be randomized (1:1) to the test group and the control group. The intervention is planned to be performed for 12\u200aweeks with a follow-up of 12\u200aweeks. All patients would be administered febuxostat (40\u200amg\/d) and concomitant anti-inflammatory prophylaxis therapy. Sinomenine and colchicine placebo are administered in the sinomenine group, sinomenine placebo and colchicine are administered in the colchicine group. The primary outcome is the rate of acute gout flares in subjects within 12\u200aweeks of the treatment period. The secondary outcomes include the times of acute gout flares and the duration of each acute flares within 12\u200aweeks; the compliance rate in patients whose UA levels \u22646.0\u200amg\/dL (360\u200a\u03bcmol\/L) at the weekend of 2nd, 4th, 8th, and 12th week in each group; the proportion of patients with \u22651 and \u22652 gout flares within 12\u200aweeks; average visual analogue scale\/score pain score during gout flares; and the oral dose of etoricoxib will be used to control the onset of acute flares within 12\u200aweeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>The Institutional Medical Ethics Committee have approved the trial protocol. We plan to publish the results of this study in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>ChiCTR, ChiCTR2100045114, Registered 8 April 2021 http:\/\/www.chictr.org.cn\/showproj.aspx?proj=124688\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029199","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T14:00:45Z","timestamp":1652450445000},"page":"e29199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-1689","authenticated-orcid":false,"given":"Ertao","family":"Jia","sequence":"first","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Hu","sequence":"additional","affiliation":[{"name":"Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Geng","sequence":"additional","affiliation":[{"name":"The Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shenzhen Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xie","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubao","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China"},{"name":"The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","article-title":"Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout","volume":"78","author":"Bursill","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jbspin.2020.05.002","article-title":"2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy","volume":"87","author":"Pascart","year":"2020","journal-title":"Joint Bone Spine"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/14656560902950742","article-title":"Gout--what are the treatment options?","volume":"10","author":"Schlesinger","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R5-20250618","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250618","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/iub.1499","article-title":"Role of sinomenine on complete Freund's adjuvant-induced arthritis in rats","volume":"68","author":"Lan","year":"2016","journal-title":"IUBMB Life"},{"key":"R9-20250618","doi-asserted-by":"crossref","first-page":"118433","DOI":"10.1016\/j.lfs.2020.118433","article-title":"Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide","volume":"261","author":"Li","year":"2020","journal-title":"Life Sci"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R11-20250618","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R12-20250618","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.3390\/molecules20046454","article-title":"An ultra-high performance liquid chromatographic-tandem mass spectrometric method for the determination of sinomenine in human plasma after transdermal delivery of the zhengqing fengtongning injection","volume":"20","author":"Chen","year":"2015","journal-title":"Molecules"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:00:47Z","timestamp":1750248047000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029199"}},"subtitle":["A randomized, positive control, double-blind, double-simulation, multicenter trial"],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":12,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029199","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"2022-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}